Adhera Therapeutics Inc (ATRX)

[EOT]

All good looking here….


“The Depository Trust Company (DTC) is an organization that acts as a central depository for securities certificates and through which member firms can transfer securities electronically via computerized bookkeeping entries.2 Physical certificates are deposited in a large securities vault located at DTC, and all securities held at DTC are registered to DTC.1 DTC appears in an issuer's stock records as the sole registered owner of securities deposited at DTC. DTC holds the deposited securities in "fungible bulk," meaning that there are no specifically identifiable shares directly owned by DTC participants. Each participant owns a pro-rata interest in the aggregate number of shares of a particular issuer held at DTC“

[mrinvestor08]

Held at DTC up from 5.8 M to 6 2 M

[EOT]

By keeping the OS this low they obviously have bigger plans…..Partners?

Outstanding Shares
8,720,090
01/11/2024

[mrinvestor08]

Eliminated almost 8 mill in debt unlike other penny pharmas out there who are sitting on high debt

[EOT]

Don’t think I’ve seen one with more potential than this.

[halbroke1]

ATRX $$$ COULD BE A HUGE BUYOUT/PARTNERSHIP TARGET!!! HUGE PHARMAS COULD BE EYEING THIS GEM BEHIND THE SCENES, $10.00+ OR MORE COULD BE VERY POSSIBLE..

[mrinvestor08]

A dangerous combo indeed ;)

[EOT]

Atrx debt free. With a pocket full of cash and great drugs lol
Tick Tock……

[mrinvestor08]

With the 640K cash ATRX could start trials ...or use that towards an uplist.

A little too quiet here. 7.8 million debt gone and management might be taking care of other things that's why not a peep from them...

[EOT]

Na just sell what ya need when it climbs…

[mrinvestor08]

Free float 2 or 3 million at most.. we all holding and not selling anytime soon not even for 30 cents...

[mrinvestor08]

Talking on this board makes the wait a bit easier lol.

Anything can happen here.

What happened to otcn on the ask? Lol

[EOT]

Adhera Therapeutics drug… MLR-1019….

“United States Patent and Trademark Office (USTPO) granted the company a patent for MLR-1019, its Parkinson’s disease candidate. The patent includes the utilization of this therapeutic to address treatment for dyskinesia linked with L-DOPA therapy in Parkinson’s disease.“


Done for a while….. later

[EOT]

“I can only dream...“

Think a LOT bigger than that!.. Like BIG Pharma!

This ticker is SO SO attractive!!
Under the radar silence will soon break imo$

[EOT]

And Roche also…..

This one was a failure…. So the page isn’t available anymore.

“Hope remains that Roche’s prasinezumab can overcome recent string of failures in Parkinson’s disease
clinicaltrialsarena.com
› home › hope remains that roche’s prasinezumab can overcome recent string of failures in parkinson’s disease
February 22, 2021 - Roche is currently developing its mAb prasinezumab after it has provided just enough evidence to proceed into a Phase IIb trial.”


Maybe Big pharma already know about Adhera’s drug?…..

.MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD.“

[EOT]

Keep an eye on Eli Lilly. They are seriously going after a Parkinson’s treatment…..

[mrinvestor08]

Let's get another deal with bdrx but this time they pay for everything all trials etc and they partner with adhera to get this Parkinsons drug to market...I can only dream...

[EOT]

Massive bidding lately. I have that feeling we are getting ready for updates and a move of all moves???

That’s Just my opinion

Ask is always so thin!

[EOT]

As soon as they speak….

[mrinvestor08]

The naked shorts will suffer very soon ;)

[EOT]

MLR-1019 is already a proven safe drug. Just waiting for the announcement….. the quiet before the storm$

[wedman]

Yes the Parkinson’s part is what interested me initially ! My dad died of als so I think on stuff a bit more now.

[EOT]

When they released the other diabetic drug it paid off their debt and made the company more secure and attractive. Adhera imo looks like it has the Parkinson’s breakthrough?



“MLR-1019 is a mirror image molecule — called an enantiomer — of mesocarb (marketed as Sidnocarb and Sydnocarb). Mesocarb is an approved medication that extends the amount of time that dopamine is available in the body by blocking cells’ ability to reabsorb it.

Melior and Adhera expect MLR-1019 to be able to boost the efficacy of L-dopa — a common medication that the brain can convert to dopamine — better than amantadine, and without that therapy’s side effects. Of note, amantadine is an oral medication approved in the U.S. to treat dyskinesia, the involuntary, jerky movements experienced by Parkinson’s patients.

This compound was first approved in the Soviet Union in 1971 and marketed for various psychiatric and neurological conditions. Mesocarb’s Russian manufacturer discontinued its production during the recession in 2008 for reasons unrelated to the compound itself.“

[wedman]

It’s worth the wait!

[EOT]

It’s very low and not difficult to own 5% here. There are always those traders that can’t hold and must trade lol, but as we see the daily volume, the smart investors hold, lock it up and wait for the company’s official update….

[mrinvestor08]

What is the locked float here...I'm gonna guess 3 million 🤔

[mrinvestor08]

Otcn sucks! Atrx management release some news!

[mrinvestor08]

They are still dumping a stock that paid off $7.8M in debt...shocking...

[sc00pnDump]

Absolutely agree

[EOT]

As of now…OTC QB….SEC compliant and up to date, and Audited. Associated with premium institutions down the line, from accounting to Nasdaq investment banks. I showed you this yesterday…..

SIC - Industry Classification
2834 - Pharmaceutical preparations

Everyone has different ways to invest and some stocks you will loose your investment because ya never know. To me i like what I see here so I will hold, add and just WAIT……..
Everyone should do their own DD!!!!!!!

[sc00pnDump]

It’s crazy seeing something like this, it’s
A real gem 💎

[EOT]

Small float, debt free, huge potential stocks like this could explode into dollars before we know anything about what’s happening here, imo. Imagine how fast shares would last here if they were speaking. It’s a do your own DD and be in before they do speak imo

At least we seen one material event filed….. it was a huge deal!!

“Biodexa Enters Worldwide Licensing Deal for Tolimidone
Published: Nov. 27, 2023

“The company agreed to pay up an up-front payment to Adhera and certain secured noteholders of Adhera, consisting of cash and American depositary shares. The company would also be obligated to pay single-digit tiered royalties on net sales of tolimidone.”

[sc00pnDump]

Yes I saw that, I’m wondering if he is still teaching in university? Smart guy

Just want to send an email on questions

This way I can plunge more money, as it is now not enough information , just have to wait.

Kind regards

[EOT]

I always look at management. This guy was appointed as CEO after serving as an atrx board member. Last month He just executed a major move to make Atrx debt free. And he said the goal was Nasdaq. When they are ready we will hear …



Zahed Subhan

Biography
Zahed Subhan, Ph.D., MBA, JD, has had over 28 years of extensive experience in guiding pre-clinical and clinical development studies, and gaining regulatory approvals from FDA and EMA agenciesfor CNS and cancer indications (both pharmaceutical and diagnostic products), as well as experience in executing major pharmaceutical product launches with multinational companies (GlaxoSmithKline, Merck & Co, Sanofi-Aventis, DuPont Pharmaceuticals). Dr. Subhan has also secured seed and venture capital funding for early stage biotechnology companies as Founder and Chief Executive Officer. As Chief Business Officer, Dr. Subhan also contributed to the $100MM IPO (NASDAQ) of a Life Sciences (Gemini Genomics) Company and its subsequent sale to Sequenom Inc for $220MM. Dr Subhan holds a PhD in Psychopharmacology from the University of Leeds, UK, an MBA from the University of Bradford, UK and a JD (Law) degree from the University of London. Dr. Subhan has over 40 publications, including 32 articles in leading Neuroscience, Clinical Pharmacology and Psychopharmacology journals. Dr. Subhan is also a Professor in Entrepreneurship and Innovation at Drexel University based in Philadelphia, USA.

[sc00pnDump]

All those patents threw Europe as well in other countries, prior Nasdaq listing, why is this company not being bought or merged into another company? Do they still own/rent their own building or subsidiaries? I’ve checked the addresses on the map more or less a group of small businesses centre.
No website no email return on the otc profile page returned 0.

Have a good day

[mrinvestor08]

the float is even smaller than we think if we take out tightly held shares...hmmm

[sc00pnDump]

Do they have proper email or something, I’ve used from the profile email and returned 0

Kind regards

[sc00pnDump]

Nice paint job, always a good sign

[EOT]

Lol it’s one person trying to take it down thinking some will dump their shares…. Haha

We’ve been waiting for news since the 8k so we will continue waiting no matter where it goes lol.
But if he takes it much lower I’ll sell something to buy huge here!, but no one’s selling so sol

Atrx…. Is a no brainer wait……..

[mrinvestor08]

How many naked shorts with otcn are here...

[sc00pnDump]

Bukwang Pharmaceuticals Co.

[sc00pnDump]

Wondering. Has anyone emailed the company and gotten a response?

[sc00pnDump]

Patience with this, it will move, also
I think news is coming


;)

[EOT]

Yes that is a major privilege. I’m amazed where this is trading right now.

[sc00pnDump]

Thankyou for that, always searching for company info never ends,

[EOT]

Atrx……
They also have this classification……

“SIC - Industry Classification
2834 - Pharmaceutical preparations”


SIC Industry Classification 2834 - Pharmaceutical preparations refers to establishments that manufacture, fabricate, or process drugs in pharmaceutical preparations for human or veterinary use. The products of these establishments are finished in the form intended for final consumption, such as ampoules, tablets, capsules, vials, ointments, medicinal powders, solutions, and suspensions.0 The industry consists of two important lines: pharmaceutical preparations promoted primarily to the dental, medical, or veterinary professions, and pharmaceutical preparations promoted primarily to the public.01 There are 1,230 companies classified in this industry in the USA, with an estimated employment of 132,663 people. The industry also includes vitamin products manufacturers, pharmaceutical laboratories, allergy laboratories, tablet makers, and nuclear medicine and supplies. Cyclopropane for anesthetic use (U.S.P. par N.F.), packaged, and sodium chloride solution for injection, U.S.P.

[sc00pnDump]

Thankyou

[EOT]

Yes. Look at the latest 10q or even read the profile on the otc page.

This Management is brilliant and well connected. Big Time.

[sc00pnDump]

Is Melior Pharmaceuticals still working with Adhera Therapeutics as far as licensing is concerned from 2 years prior?

Have a good day

[mrinvestor08]

Management team very quiet after eliminating $7.8M in debt....